Table 2. Comparative 5 and 10 year event rates for luminal A and B.

	IBTR		LRR		DM		BCSD
	5 Year (%)	10 Year (%)	5 Year (%)	10 Year (%)	5 Year (%)	10 Year (%)	5 Year (%)	10 year (%)
Whole cohort (n=498)	12/498 (2.4)	23/498 (4.6)	21/498 (4.2)	35/498 (6.8)	34/498 (6.8)	47/498 (9.4)	18/498 (3.6)	37/498 (7.4)
	12/24 (50)	23/24 (95.8)	21/35 (60)	35/35 (100)	34/47 (72.3)	47/47 (100)	18/37 (48.6)	37/37 (100)
Luminal A (n=394)	4/394 (1)	14/394 (3.6)	8/394 (2)	19/394 (4.8)	19/394 (4.8)	30/394 (7.6)	7/394 (1.8)	23/394 (5.8)
	4/15 (26.6)	14/15 (93.3)	8/20 (40)	19/20 (95)	19/30 (63.3)	30/30 (100)	7/23 (30.4)	23/23 (100)
Luminal B (n=23)	1/23 (4.3)	2/23 (8.7)	1/23 (4.3)	2/23 (8.6)	2/23 (8.6)	2/23 (8.6)	1/23 (4.3)	2/23 (8.6)
	1/2 (50)	2/2 (100)	1/2 (50)	2/2 (100)	2/2 (100)	2/2 (100)	1/2 (50)	2/2 (100)
Modified luminal A (n=321)	2/321 (0.6)	9/321 (2.8)	3/321 (0.9)	11/321 (3.4)	9/321 (2.8)	16/321 (4.9)	1/321 (0.3)	11/321 (3.4)
	2/9 (22.2)	9/9 (100)	3/11 (27)	11/11 (100)	9/16 (56.3)	16/16 (100)	1/11 (9.1)	11/11 (100)
Modified luminal B (n=96)	3/96 (3.1)	7/96 (7.3)	6/96 (6.3)	10/91 (10.9)	12/96 (12.5)	16/96 (16.7)	7/96 (7.3)	14/96 (14.6)
	3/8 (37.5)	7/8 (87.5)	6/11 (54.5)	10/11 (90.1)	12/16 (75)	16/16 (100)	7/14 (50)	14/14 (100)

Abbreviations: BCSD=breast cancer-specific death; DM=distant metastasis; ER+ =oestrogen receptor positive; IBTR=ipsilateral breast tumour recurrence; LRR=locoregional recurrence; PR+ =progesterone receptor positive.

Modified luminal A: ER+ and/or PR+, Ki-67 low, p53−, HER2− modified luminal B: ER+ and/or PR+ and/or Ki-67 high and/or p53+ and/or HER2+. In the top row of each box, the denominator is the total number of patients within that patient group or subtype; in the bottom row of each box, the denominator is the total number of events for each group or subtype.